Fig. 6.

Gemcitabine therapy reduces MDSC in the peripheral blood of patients with pancreatic cancer. a Percentage of CD14⁻CD11b⁺CD33⁺ cells in the PBMC of healthy donors and pancreatic cancer patients as measured by flow cytometry. b Percentage of CD14⁻CD11b⁺CD33⁺ cells in the PBMC of pancreatic cancer patients prior to Gem therapy (pre) and after 1 cycle of 1000 mg/m² Gem therapy (post-Gem) as measured by flow cytometry. *p < 0.05; **p < 0.01